benzoic acid-(17-hydroxy-19-nor-17βH-pregnatrien-(A)-yn-(20)-yl-(3)-ester) | 5934-04-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: benzoic acid-(17-hydroxy-19-nor-17βH-pregnatrien-(A)-yn-(20)-yl-(3)-ester)
• 英文别名: Benzoesaeure-(17-hydroxy-19-nor-17βH-pregnatrien-(A)-in-(20)-yl-(3)-ester)；3-benzoyloxy-17α-ethinyl-1,3,5(10)-estratrien-17β-ol；17α-ethinyl estradiol benzoate；17alpha-Ethynylestradiol 3-benzoate；[(8R,9S,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] benzoate
• CAS: 5934-04-3
• 化学式: C₂₇H₂₈O₃
• 分子量: 400.518
• InChiKey: PQPDFKSTDGKONX-IUJPGNIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  benzoic acid-(17-hydroxy-19-nor-17βH-pregnatrien-(A)-yn-(20)-yl-(3)-ester) 在 N-碘代丁二酰亚胺 、 silver nitrate 作用下， 以 丙酮 为溶剂， 反应 0.5h， 以65%的产率得到3-Benzoyloxy-17α-iodethinyl-1,3,5(10)-oestratrien-17β-ol
  参考文献：
  名称：

  Hofmeister, Helmut; Annen, Klaus; Laurent, Henry, Angewandte Chemie, 1984, vol. 96, # 9, p. 720 - 722

  摘要：

  DOI：
• 作为产物：
  描述：

  炔雌醇 、 苯甲酰氯 在 氢氧化钾 作用下， 生成 benzoic acid-(17-hydroxy-19-nor-17βH-pregnatrien-(A)-yn-(20)-yl-(3)-ester)
  参考文献：
  名称：

  Inhoffen et al., Chemische Berichte, 1938, vol. 71, p. 1024,1030

  摘要：

  DOI：

文献信息

• Estrogenic 17.alpha.-halogen-vinylestranes
  申请人：Schering Aktiengesellschaft

  公开号：US04725426A1

  公开（公告）日：1988-02-16

  17.alpha.-bromo-.alpha. and 17.alpha.-iodo-vinyl-estrane derivatives of general formula I ##STR1## wherein X is a bromine or iodine atom in Z or E position, R.sup.1 is hydrogen, hydroxy or acyloxy with up to 3 C atoms, R.sup.2 is hydrogen, alkyl with up to 3 C atoms and alkanoyl and aroyl with up to 7 C atoms, R.sup.3 is hydrogen or methyl, R.sup.4 is a hydrogen atom in the .alpha. or .beta. position, R.sup.5 is hydrogen, methyl or methoxy and R.sup.6 is hydrogen or methyl, are pharmacologically effective with a profile of action like ethinylestradiol and in the form of their radioactively labeled compounds are also valuable diagnostic media. The Z-isomers can be prepared by a new process by reaction of the corresponding 17.alpha.-ethinyl steroids with trialkyl (or phenyl) tin hydride with addition of a free radical former.

  17.alpha.-溴-.alpha.和17.alpha.-碘-乙烯基-雌甾烷衍生物的一般化学式I如下：其中X是Z或E位置的溴或碘原子，R.sup.1是氢、羟基或酰氧基，碳原子数最多为3，R.sup.2是氢、碳原子数最多为3的烷基以及碳原子数最多为7的烷酰基和芳酰基，R.sup.3是氢或甲基，R.sup.4是.alpha.或.beta.位置的氢原子，R.sup.5是氢、甲基或甲氧基，R.sup.6是氢或甲基，具有药理学作用，其作用特点类似于乙炔雌二醇，并且以其放射性标记化合物的形式也是有价值的诊断介质。Z-异构体可以通过一种新的方法制备，即将相应的17.alpha.-乙炔类固醇与三烷基（或苯基）锡氢化合物反应，并加入自由基前体。
• Ladder-Frame Polyether Conjugates
  申请人：Bourdelais Andrea

  公开号：US20120077778A1

  公开（公告）日：2012-03-29

  Disclosed are compounds that are conjugates of ladder frame polyether compounds and biologically active compounds or research compounds, pharmaceutical formulations comprising the conjugates, and methods of transporting the conjugates across biological membranes.

  揭示了梯架框架聚醚化合物和生物活性化合物或研究化合物的共轭物、包含这些共轭物的药物配方，以及将这些共轭物跨越生物膜的方法。
• Mucosal formulation
  申请人：Boga Rameshbabu

  公开号：US20070264206A1

  公开（公告）日：2007-11-15

  A mucosal formulation for administration to mucosal membranes, such as in the mouth, nasal passage, stomach, vagina, etc., is disclosed. The mucosal formulation contains a lipid-pharmaceutical agent complex formed from phospholipids possessing a hydrophobic moiety that orients into a hydrophobic phase and a polar head moiety that orients towards the aqueous phase (i.e., “amphipathic” lipids). When placed in an aqueous medium (e.g., vaginal fluid), the phospholipids form liposomes or other small lipid vesicles (e.g., micelles) that may then be used to deliver pharmaceutical agents into a living organism.

  揭示了一种用于给粘膜膜的制剂，例如口腔、鼻腔、胃、阴道等。这种粘膜制剂包含从磷脂中形成的含有疏水部分的脂质-药物复合物，该疏水部分朝向疏水相，极性头部分朝向水相（即“两性”脂质）。当置于水性介质中（例如阴道液），磷脂形成脂质体或其他小的脂质囊泡（例如胶束），然后可用于将药物输送到活体内。
• Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
  申请人：——

  公开号：US20030133985A1

  公开（公告）日：2003-07-17

  Erodible, gastric-retentive dosage forms are provided that are formulated using the in vitro drug release profile obtained with USP Disintegration test equipment rather the USP Dissolution Apparatus. The invention is premised on the discovery that the USP Disintegration Test and modified versions thereof are far more predictive of the in vivo release profile for a controlled release dosage form than is the standard USP Dissolution Test, particularly controlled release dosage forms of the swellable, erodible type. The dosage forms generally comprise particles of a biocompatible, hydrophilic polymer having the active agent incorporated therein, wherein the particles are optionally but preferably compacted into a tablet or loaded into a capsule. The dosage forms can be used to deliver water-insoluble or sparingly soluble drugs as well as water-soluble drugs, providing that the latter are coated with a protective coating or contained in a protective vesicle.

  提供可侵蚀的、胃滞留的剂型，其配方使用USP分散测试设备获得的体外药物释放剖面，而不是USP溶解器。该发明是基于发现，USP分散测试及其修改版本比标准的USP溶解测试更能预测可控释放剂型的体内释放剖面，特别是膨胀、侵蚀型的可控释放剂型。该剂型通常包括生物相容性、亲水性聚合物的颗粒，其中活性成分被纳入其中，颗粒可以选择但最好是压缩成片剂或装入胶囊。该剂型可用于输送水不溶性或难溶性药物，以及水溶性药物，前提是后者被涂上保护涂层或包含在保护小囊中。
• Formulation of an erodible, gastric retentive oral diuretic
  申请人：——

  公开号：US20030152622A1

  公开（公告）日：2003-08-14

  An erodible, gastric-retentive oral diuretic is provided that is formulated using the in vitro drug release profile obtained with USP Disintegration test equipment rather the USP Dissolution Apparatus. The invention is premised on the discovery that the USP Disintegration Test and modified versions thereof are far more predictive of the in vivo release profile for a controlled release dosage form than is the standard USP Dissolution Test, particularly controlled release dosage forms of the swellable, erodible type. The dosage forms generally comprise particles of a biocompatible, hydrophilic polymer having the active agent incorporated therein, wherein the particles are optionally but preferably compacted into a tablet or loaded into a capsule. The dosage forms can be used to deliver water-insoluble or sparingly soluble drugs as well as water-soluble drugs, providing that the latter are coated with a protective coating or contained in a protective vesicle. Using the controlled release dosage form, adverse side effects associated with peak diuresis are diminished or eliminated, while the overall diuretic effect of the drug is maintained.

  提供了一种可侵蚀、胃内停留的口服利尿剂，其配方使用了通过美国药典溶解试验设备获得的体外药物释放特性，而不是使用美国药典溶出仪。该发明基于发现，美国药典溶解试验及其修改版本远比标准的美国药典溶出试验更具预测性，特别是对于可膨胀、可侵蚀类型的控释剂型的体内释放特性。这些剂型通常包括含有活性成分的生物相容性、亲水性聚合物颗粒，其中这些颗粒可以选择性地但最好是被压制成片剂或装入胶囊中。这些剂型可用于输送水不溶性或难溶性药物以及水溶性药物，只要后者被覆盖有保护层或包含在保护泡囊中。使用控释剂型，可以减轻或消除与高峰利尿相关的不良副作用，同时保持药物的整体利尿效果。